Dr. Giovanni Luca Frassineti - Oncologia Rimini

More documents

Recommendations

Info

CARCINOMA DEL COLON: BEVACIZUMAB DOPO PROGRESSIONE A.Grothey, et al. JCO 2008 BRiTE TRIAL Post-progression Avastin: HR=0.48 (95% CI: 0.41–0.57) p
Rapid vascular regrowth in tumors after reversal of VEGF inhibition. Michael R. Mancuso
Page 1 and 2: Luca Frassineti e Andrea Casadei Ga
Page 3 and 4: Sviluppo storico della chemioterapi
Page 5 and 6: IL CAMBIAMENTO DELLA MODERNA PATOLO
Page 7: Targeted Therapies • Gli “umab
Page 11 and 12: Past Selection of a chemical entity
Page 13 and 14: STUDI DI FASE II Terapie a bersagli
Page 15 and 16: STUDI DI FASE III AGENTE CITOTOSSIC
Page 18: Progressi terapeutici nel tumore de
Page 21 and 22: TARGET THERAPY NEL CARCINOMA DEL PO
Page 23 and 24: TARGET THERAPY NEL CARCINOMA RENALE
Page 25 and 26: TARGET THERAPY NEL CARCINOMA DELLO
Page 27 and 28: Sorafenib in advanced HCC •SHARP
Page 30 and 31: TARGET THERAPY NELL’ADIUVANTE DEL
Page 32 and 33: Problematiche “aperte” Associaz
Page 34 and 35: Completely resected stage III colon
Page 38 and 39: CARCINOMA DELLA MAMMELLA: TRASTUZUM
Page 40 and 41: Tabernero J, et al. ASCO 2010. Abst
Page 42 and 43: Problematiche “aperte” ASSOCIAZ
Page 44: J. O'Shaughnessy ASCO 2008 Kimberly
Page 47 and 48: FARMACI BEN TOLLERATI MA………
Page 49 and 50: Hurwitz H, et al. N Engl J Med 2004
Page 51 and 52: 1.0 0.9 Grade 2-4 Grade 1 0.8 Survi
Page 53 and 54: Risk of cardiac dysfunction with tr
Page 56 and 57: CA MAMMARIO TERAPIA ADIUVANTE REGIM
Page 58 and 59: New anticancer drugs First therapeu

Dr. Giovanni Luca Frassineti - Oncologia Rimini

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?